The relationship between renal activity and quality of life in systemic lupus erythematosus

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 947-952

  Appenzeller, Simone ^a   Clarke, Ann E ^a   Panopalis, Pantelis ^b   Joseph, Lawrence ^a,c   St Pierre, Yvan ^a   Li, Tracy ^d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Hierarchical modeling; Quality of life; Renal activity; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; EVALUATION RESEARCH; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; DAILY LIFE ACTIVITY; DISABILITY; HEALTH STATUS; HOSPITALIZATION; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; SICKNESS IMPACT PROFILE;

ACTIVITIES OF DAILY LIVING; ADULT; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HUMANS; LUPUS NEPHRITIS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 67449099216     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080822     Document Type: Article

References (37)

1. Kuriya B, Gladman DD, Ibanez D, Urowitz MB. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008;59:181-5.
2. Gilboe IM, Kvien TK, Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. J Rheumatol 1999;26:1694-700.
3. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005;32:1706-8.
4. Perez-Cuevas JB, Formiga F, Garcia-Carrasco M, Ramos M, Lara C, Rojas-Rodriguez J. A quality of life study in women with systemic lupus erythematosus and its relation to disease activity [Spanish]. An Med Interna 1999;16:457-60.
5. Friedman AW, Alarcon GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature versus Nurture. Arthritis Care Res 1999;12:256-66.
6. Thumboo J, Fong KY, Chan SP, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000;27:1414-20.
7. Sutcliffe N, Clarke AE, Levinton C, Frost C, Gordon C, Isenberg DA. Associates of health status in patients with SLE. J Rheumatol 1999;26:2352-6.
8. Devins GM, Edworthy SM. Illness intrusiveness explains race-related quality-of-life differences among women with systemic lupus erythematosus. Lupus 2000;9:534-41.
9. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology 2004;43:1580-6.
10. Panopalis P, Petri M, Manzi S, et al. The systemic lupus erythematosus tri-nation study: Longitudinal changes in physical and mental well-being. Rheumatology 2005;44:751-5.
11. Alarcon GS, McGwin G Jr, Uribe A, et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004;51:465-74.
12. Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608-14.
13. Saba J, Quinet RJ, Davis WE, et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine 2003;70:348-51.
14. Fortin PR, Abrahamowicz M, Neville C, et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998;7:101-7.
15. Dobkin PL, DaCosta D, Dritsa M, et al. Quality of life in SLE during more and less active disease states: Differential contributors to mental and physical health. Arthritis Care Res 1999;12:401-10.
16. Medeiros MM, Menezes AP, Silveira VA, Ferreira FN, Lima GR, Ciconelli RM. Health-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Med 2008;19:122-8.
17. Bae SC, Hashimoto H, Karlson EW, Liang MH, Daltroy LH. Variable effects of social support by race, economic status, and disease activity in systemic lupus erythematosus. J Rheumatol 2001;28:1245-51.
18. Hanly JG. Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: results of a cross-sectional study. Lupus 1997;6:243-7.
19. Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology 2004;43:1536-40.
20. Freire EA, Maia IO, Nepomuceno JC, Ciconelli RM. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clin Rheumatol 2007;26:423-8.
21. Gladman DD, Urowitz MB, Gough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol 1997;24:2145-8.
22. Wang C, Mayo NE, Fortin PR. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol 2001;28:525-32.
23. Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front Biosci 2008;13:3312-20.
24. Vu TV, Escalante A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease. J Rheumatol 1999;26:2595-601.
25. Tse KC, Tang CS, Lio WI, Lam MF, Chan TM. Quality of life comparison between corticosteroid and mycofenolate mofetil and corticosteroid and oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus 2006;15:371-9.
26. Grootscholten C, Snoek FJ, Bijl M, van Houwelingen HC, Derksen RH, Berden JH. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/methylprednisolone in a randomized controlled trial. J Rheumatol 2007;34:1699-707.
27. Clarke AE, Panopalis P, Petri M, et al. SLE patients with renal damage incur higher health care costs. Rheumatology 2008;47:329-33.
28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
29. Ware JE Jr, Sherbourne CD. The MOS 36 item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
30. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
31. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
32. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics Computing 2000;10:325-37.
33. Strand V, Aranow C, Cardiel MH, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86.
34. Rinaldi S, Doria A, Salaffi F, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology 2004;43:1574-9.
35. Campbell R Jr, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum 2008;59:458-64.
36. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953-62.
37. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.